Study identifies inflammatory immune pathway driving immunotherapy resistance in bladder cancer

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well to immunotherapy. Their findings, published in Cancer Discovery, show that common signs of inflammation in the blood are linked to immune cells inside tumors that block the body’s ability to fight cancer.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup